Printer Friendly

U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS TO PRODUCTS IN LATIN AMERICA AND FAR EAST

 U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS
 TO PRODUCTS IN LATIN AMERICA AND FAR EAST
 WEST CONSHOHOCKEN, Pa., March 16 /PRNewswire/ -- U.S. Bioscience Inc. (AMEX: UBS), a pharmaceutical company specializing in the development and commercialization of anti-cancer compounds, today announced that the company has signed a definitive agreement with Schering-Plough Corp. (NYSE: SGP), granting it marketing rights to Hexalen(R), Ethyol(R), WR-151327, PALA and Rogletimide for over 35 countries in Latin America and the Far East, including Mexico, Brazil, Argentina, India and the People's Republic of China.
 Hexalen has been approved by the U.S. Food and Drug Administration and is used in the treatment of ovarian cancer. Ethyol, for which a New Drug Application has been filed with the FDA, is under development as a chemotherapy- and radiation-protective agent. PALA, a drug in the final stages of development, is aimed at enhancing the activity of certain chemotherapeutic agents. Rogletimide is a drug under development for the treatment of breast cancer.
 "In Schering-Plough, we have chosen a company that historically has had strong marketing, sales and product registration capabilities in the oncology market, which will help to optimize the potential of these products in these regions," said Philip S. Schein, M.D., chairman and chief executive officer. "We are pleased to be associated with this organization. The completion of this agreement represents an important step to the company as we expand our efforts internationally in markets where U.S. Bioscience may have a limited chance of succeeding on its own."
 Schering-Plough Corp., of Madison, N.J., is a research-based company involved in the discovery, development, manufacturing and marketing of pharmaceutical and healthcare products worldwide.
 Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases.
 -0- 3/16/92
 EDITOR'S NOTE: An agreement in principle was annoounced Nov. 19, 1991.
 /CONTACT: Robert I. Kriebel of U.S. Bioscience Inc., 215-832-4503, or Charles Versaggi of Versaggi & Associates, 408-358-4162 or 408-395-1877, for U.S. Bioscience Inc./
 (UBS SGP) CO: U.S. Bioscience Inc.; Schering-Plough Corp. ST: Pennsylvania; New Jersey IN: MTC SU: LIC


RF -- SJ002 -- 8101 03/16/92 08:05 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 16, 1992
Words:375
Previous Article:SYMANTEC ANNOUNCES NEW, MORE POWERFUL VERSION OF JUSTWRITE WINDOWS WORD PROCESSOR
Next Article:JACOBS RECEIVES AWARD OF MERIT FOR DESIGN OF BORDEN HYPER PLANT (JACOBS ENGINEERING GROUP)
Topics:


Related Articles
U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS TO PRODUCTS IN LATIN AMERICA AND FAR EAST
SCHERING-PLOUGH AND U.S. BIOSCIENCE
SCHERING-PLOUGH LICENSES ORAL ANDROGEN TO SPI PHARMACEUTICALS
SCHERING-PLOUGH AND ORION SIGN AGREEMENT ON U.S. MARKETING RIGHTS FOR BREAST CANCER TREATMENT
ALZA AND U.S. BIOSCIENCE ANNOUNCE MARKETING AND DISTRIBUTION AGREEMENT FOR ETHYOL(R) IN THE UNITED STATES
Schering-Plough Sells Rights to Interleukin-11 to American Home Products Corporation
Schering-Plough and Reckitt & Colman in Agreement on Worldwide Marketing Rights for Buprenorphine Products
Schering-Plough and Chugai Pharmaceutical In Agreement on Marketing Rights For New Treatment of Psoriasis
Helsinn Healthcare SA and Schering-Plough announce licensing agreement for palonosetron in select global markets.
Schering-Plough and Helsinn Healthcare SA Announce Licensing Agreement For Palonosetron in Select Global Markets.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters